A Phase 3 interventional study of CTP-543 in Alopecia Areata, sponsored by Sun Pharmaceutical Industries, Inc.. Completed at 39 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Sun Pharmaceutical Industries, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 8th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 407 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Sun Pharmaceutical Industries, Inc., one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Sun Pharmaceutical Industries, Inc. is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 8th registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata. Patients from European sites who previously completed a qualifying CTP-543 clinical trial may participate in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who previously completed a qualifying CTP-543 clinical trial
Drug: CTP-543
Twice daily dosing
Number of Participants With Adverse Events as a Measure of Safety
Time frame: 108 weeks
Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). This outcome measures the relative Change from Pre-zero Baseline in Total SALT Scores. Relative change from baseline was defined as 100\*(post-baseline value - baseline)/baseline.
Time frame: 108 weeks
| Milestone | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|
| Started | 255 | 152 |
| Completed | 201 | 127 |
| Not completed | 54 | 25 |
| Participants | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety | 308 | 224 |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). This outcome measures the relative Change from Pre-zero Baseline in Total SALT Scores. Relative change from baseline was defined as 100\*(post-baseline value - baseline)/baseline.
| Percentage change | CTP-543 8 mg BID | CTP-543 8 mg BID to CTP-543 12 mg BID | CTP-543 12 mg BID to CTP-543 8 mg BID |
|---|---|---|---|
| Relative Change From Pre-zero Baseline in Total Severity of Alopecia Tool (SALT) Scores at Week 108 | -96.38 ± 8.790 | -88.57 ± 18.715 | -90.25 ± 18.860 |
Collected over 108 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CTP-543 8 mg BID | 0/367 (0%) | 16/367 (4.4%) | 176/367 (48%) |
| CTP-543 12 mg BID | 0/273 (0%) | 5/273 (1.8%) | 127/273 (46.5%) |
| Event | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/367 | 0/273 |
| Bartholin's abscessInfections and infestations | 0/367 | 1/273 |
| Humerus fractureInjury, poisoning and procedural complications | 0/367 | 1/273 |
| Synovial cystMusculoskeletal and connective tissue disorders | 0/367 | 1/273 |
| Abdominal painGastrointestinal disorders | 1/367 | 1/273 |
| Tongue neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/367 | 1/273 |
| Bartholin's cystReproductive system and breast disorders | 0/367 | 1/273 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/367 | 1/273 |
| Hepatitis EInfections and infestations | 1/367 | 0/273 |
| Infectious mononucleosisInfections and infestations | 1/367 | 0/273 |
| Event | CTP-543 8 mg BID | CTP-543 12 mg BID |
|---|---|---|
| Asymptomatic COVID-19Infections and infestations | 83/367 | 58/273 |
| COVID-19Infections and infestations | 78/367 | 44/273 |
| NasopharyngitisInfections and infestations | 76/367 | 48/273 |
| Blood creatine phosphokinase increasedInvestigations | 42/367 | 24/273 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 41/367 | 29/273 |
| ThrombocytosisBlood and lymphatic system disorders | 20/367 | 26/273 |
| Upper respiratory tract infectionInfections and infestations | 30/367 | 14/273 |
| HeadacheNervous system disorders | 23/367 | 9/273 |
| AnaemiaBlood and lymphatic system disorders | 13/367 | 14/273 |
| Weight increasedInvestigations | 14/367 | 14/273 |
| Age, Continuous(years) | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|
| Mean | 38.9 ± 12.41 | 38.2 ± 12.86 | 38.7 ± 12.57 |
| Sex: Female, Male(Participants) | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|
| Female | 181 | 89 | 270 |
| Male | 74 | 63 | 137 |
| Ethnicity (NIH/OMB)(Participants) | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 5 | 12 |
| Not Hispanic or Latino | 186 | 117 | 303 |
| Unknown or Not Reported | 62 | 30 | 92 |
| Race (NIH/OMB)(Participants) | CTP-543 8 mg BID | CTP-543 12 mg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 193 | 121 | 314 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 62 | 30 | 92 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2021 to primary completion in Jul 2024, 32 months.
Results were first posted in Nov 2025, 1 year 4 months after primary completion.
Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib
Sun Pharmaceutical Industries, Inc. →